CSIMarket
 
Sana Biotechnology Inc   (SANA)
Other Ticker:  
 
 
Price: $11.2700 $1.23 12.251%
Day's High: $12 Week Perf: 33.37 %
Day's Low: $ 10.84 30 Day Perf: 105.28 %
Volume (M): 5,333 52 Wk High: $ 12.00
Volume (M$): $ 60,105 52 Wk Avg: $5.10
Open: $11.50 52 Wk Low: $2.75



 Market Capitalization (Millions $) 2,259
 Shares Outstanding (Millions) 200
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -280
 Cash Flow (TTM) (Millions $) -46
 Capital Exp. (TTM) (Millions $) 10

Sana Biotechnology Inc
Sana Biotechnology Inc is a biotechnology company that focuses on cell engineering to create and deliver transformative cures for patients suffering from various diseases. The company utilizes advancements in stem cell biology, gene editing technologies, and other cellular therapies to develop novel treatments. Sana Biotechnology aims to tackle complex and challenging diseases by engineering cells to repair, replace, and enhance the body's natural functions. Their goal is to provide patients with new, advanced therapies that have the potential to significantly improve their quality of life.


   Company Address: 188 East Blaine Street Seattle 98102 WA
   Company Phone Number: 701-7914   Stock Exchange / Ticker: NASDAQ SANA
   SANA is expected to report next financial results on March 06, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Sana Biotechnology's HIP-modified Cell Therapies: A New Era for Diabetes and Cancer Treatmentn

Published Tue, Feb 13 2024 9:05 PM UTC

Sana Biotechnology's HIP-modified Cell Therapies Show Promising Results in Diabetes and Cancer TreatmentSEATTLE, Dec. 01, 2023 - Sana Biotechnology, a company dedicated to revolutionizing patient care through engineered cells, has recently published important data showcasing the potential breakthroughs of their hypoimmune-modified (HIP) cell therapies in the treatment of dia...

Financing Agreement

Sana Biotechnology Announces Successful Completion of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares

Published Mon, Feb 12 2024 9:06 PM UTC

Sana Biotechnology Announces Successful Completion of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
SEATTLE, Feb. 12, 2024 - Sana Biotechnology, Inc. (Nasdaq: SANA), a pioneering biotechnology company focused on revolutionizing patient care through the use of engineered cells, proudly announced today the successful closing...

Management Announcement

Sana Biotechnology: Pioneering Patient Care Through Strategic Investment

Published Thu, Feb 8 2024 6:22 AM UTC


Sana Biotechnology Sets New Course with Upsized Public Offering
In a bold move that demonstrates its commitment to revolutionizing patient care, Sana Biotechnology, Inc. recently revealed the pricing details for its upsized public offering. The company aims to raise approximately $165.0 million in gross proceeds through the sale of 17,272,728 shares of common stock,...

Clinical Study

Sana Biotechnology's SC262 CAR T Therapy Receives FDA Clearance; Promises New Horizon for B-cell Malignancy Treatment

Published Fri, Jan 5 2024 2:00 PM UTC

Sana Biotechnology Inc. has achieved a great milestone by obtaining a clearance for their Investigational New Drug Application for SC262 from the U.S. Food and Drug Administration (FDA). This breakthrough is seen as a significant step towards broadening the range of treatment options available to patients suffering from B-cell malignancies that have either recurred or resist...

Clinical Study

Groundbreaking Preclinical Data Highlights the Revolutionary Potential of Sana Biotechnology's Allogeneic CAR T Cells in Tumor Control and Immune Evasion

Published Mon, Dec 11 2023 2:00 PM UTC



Sana Biotechnology, a leading biotechnology company, presented groundbreaking preclinical data at the American Society of Hematology Annual Meeting, shedding light on the remarkable abilities of their hypoimmune-modified allogeneic CAR T cells. These findings have further strengthened the completed IND submission for SC262, a HIP-modified CD22-directed allogeneic C...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com